Array BioPharma’s Post-Approval Business Strategy Stymied

 
• By John Davis
  
Generate a summary of this article
Listen to this article
Beta

Following a meeting with the US FDA, Array BioPharma has withdrawn the NDA for its MEK inhibitor binimetinib because of insufficient evidence of clinical benefit in a tough-to-treat subgroup of melanoma patients, that may lead to a rethink of its commercialization strategy.

Melanoma

The US biotech Array BioPharma Inc. says its withdrawal of the US NDA for the MEK inhibitor binimetinib for the treatment of NRAS-mutant melanoma will not affect the filing of the combination, binimetinib plus the BRAF inhibitor encorafenib, in the larger indication, BRAF-mutant melanoma, but the stock market was still disappointed with the withdrawal, with the company’s share price knocked down by 34% in pre-market trading on March 20.

The decision will likely disrupt Array BioPharma’s overall business strategy based on using the approval and introduction of lead product...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.